The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands

被引：35

作者：

Leunis, Annemieke ^{[1
]}

Blommestein, Hedwig M. ^{[1
]}

Huijgens, Peter C. ^{[2
]}

Blijlevens, Nicole M. A. ^{[3
]}

Jongen-Lavrencic, Mojca ^{[4
]}

Uyl-de Groot, Carin A. ^{[1
]}

机构：

[1] Erasmus Univ, Inst Hlth Policy & Management, Inst Med Technol Assessment, NL-3000 DR Rotterdam, Netherlands

[2] Vrije Univ Amsterdam, Med Ctr Amsterdam, Dept Hematol, Amsterdam, Netherlands

[3] Univ Med Ctr St Radboud Nijmegen, Dept Hematol, Nijmegen, Netherlands

[4] Erasmus MC, Dept Hematol, Rotterdam, Netherlands

来源：

LEUKEMIA RESEARCH | 2013年 / 37卷 / 03期

关键词：

Costs; Acute myeloid leukemia; Induction treatment; Consolidation treatment; Follow-up; Cost components; INDUCTION CHEMOTHERAPY; REDUCED-INTENSITY; ELDERLY-PATIENTS; STRATEGIES; MANAGEMENT; DIAGNOSIS; REGIMENS;

D O I：

10.1016/j.leukres.2012.09.018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The aim of this study was to calculate the costs of the current initial treatment of acute myeloid leukemia. Resource use was collected for 202 patients who started with intensive chemotherapy in 2008 or 2009. The costs of the first induction course were significantly higher than the costs of the second induction course. Allogeneic transplantation from a matched unrelated donor was significantly more expensive than the other consolidation treatments. In-hospital stay was the major cost driver in the treatment of AML. Research regarding possibilities of achieving the same or better health outcome with lower costs is warranted. (C) 2012 Elsevier Ltd. All rights reserved.

引用

页码：245 / 250

页数：6

共 23 条

[1]

[Anonymous], 2010, HANDLEIDING KOSTENON

[2]

Blommestein HM, 2012, ANN HEMATOL

[3] Therapeutic Advances in Acute Myeloid Leukemia [J].

Burnett, Alan ;

Wetzler, Meir ;

Loewenberg, Bob .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (05) :487-494

[4] Do minitransplants have minicosts?: A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia [J].

Cordonnier, C ;

Maury, S ;

Esperou, H ;

Pautas, C ;

Beaune, J ;

Rodet, M ;

Lagrange, JL ;

Rouard, H ;

Beaumont, JL ;

Bassompierre, F ;

Glückman, E ;

Kuentz, M ;

Durand-Zaleski, I .

BONE MARROW TRANSPLANTATION, 2005, 36 (07) :649-654

[5]

Cornelissen Jan J, 2005, Hematology Am Soc Hematol Educ Program, P151

[6] Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet [J].

Doehner, Hartmut ;

Estey, Elihu H. ;

Amadori, Sergio ;

Appelbaum, Frederick R. ;

Buechner, Thomas ;

Burnett, Alan K. ;

Dombret, Herve ;

Fenaux, Pierre ;

Grimwade, David ;

Larson, Richard A. ;

Lo-Coco, Francesco ;

Naoe, Tomoki ;

Niederwieser, Dietger ;

Ossenkoppele, Gert J. ;

Sanz, Miguel A. ;

Sierra, Jorge ;

Tallman, Martin S. ;

Loewenberg, Bob ;

Bloomfield, Clara D. .

BLOOD, 2010, 115 (03) :453-474

[7] Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) [J].

Estey, Elihu ;

de Lima, Marcos ;

Tibes, Raoul ;

Pierce, Sherry ;

Kantarjian, Hagop ;

Champlin, Richard ;

Giralt, Sergio .

BLOOD, 2007, 109 (04) :1395-1400

[8]

Eurostat, 2012, EUROECU EXCHANG RAT

[9]

Franken MG, 2012, PILOT OUTCOMES RES E

[10] Recent developments in acute myelogenous leukemia therapy [J].

King, Mary E. ;

Rowe, Jacob M. .

ONCOLOGIST, 2007, 12 :14-21

← 1 2 3 →